Treatment of small hepatocellular carcinoma associated with cirrhosis by percutaneous ethanol injection. A trial with a comparison group

Orlando A, Cottone M, Virdone R, Parisi P, Sciarrino E, Maringhini A, Caltagirone M, Simonetti RG, Pagliaro L.Scand J Gastroenterol. 1997 Jun;32(6):598-603.PMID: 9200294

Abstract

Background: Ethanol injection has been reported to be effective in the treatment of hepatocellular carcinoma, but no controlled randomized trials have been performed. We therefore performed a trial comparing ethanol injection with an untreated, matched historical comparison group in the treatment of hepatocellular carcinoma.

Methods: From 1992 to 1993, 35 patients (14 Child’s A and 21 Child’s B cirrhosis) with small (< 4 cm) hepatocellular carcinoma associated with cirrhosis were treated by ethanol injection. Each patient was matched with an untreated case (followed up during the period 1984-89) for variables known to have independent prognostic value (age, Child’s classification, number of lesions, alpha-fetoprotein, and modality of diagnosis).

Results: The 1-, 2-, and 3-year survival rates of ethanol-treated patients were 86% (95% confidence interval (CI), 69-94), 53% (95% CI, 34-68), and 33% (95% CI, 15-52), whereas the survival rates of the comparison group were 75% (95% CI, 56-85), 26% (95% CI, 13-41), and 14% (95% CI, 5-27) (P = 0.01). The 1-, 2-, and 3-year survival rates of Child’s A were 100%. 87% (95% CI, 30-97), 71% (95 CI, 33-90), 71% (95% CI, 33-90) in the ethanol-treated patients and 92 (95% CI, 59-99), 43% (95% CI, 23-73), and 21% (95% CI, 23-72) in untreated patients. The 1-, 2-, and 3-year survival of Child’s B patients were 76% (95% CI, 59-97), 32% (95% CI, 13-53), and 9% (95% CI, 0.8-33) in the treated group and 61% (95% CI, 40-83), 14% (95% CI, 3-32), and 9% (95% CI, 1-26) in the treated group.

Conclusions: These data suggest that ethanol injection prolongs the life of patients with hepatocellular carcinoma associated with Child’s A cirrhosis but seems not to influence the survival of Child’s B patients.

Link PubMEd


Altre pubblicazioni

INFO
immagine_profilo
Alberto Maringhini
Direttore Medicina Interna 1
ARNAS Civico
Research gate score
  • Research Interests: 996.7
  • Citations: 1.973
  • h-index: 26
ATTIVITÀ DI RICERCA IN CORSO
Screening del cancro del pancreas: un trial controllato
Coordinatori dello studio
  • Dott. Alberto Maringhini
  • Dott.ssa Rosalia Patti
  • Dott.ssa Anna Riili
  • Dott.ssa Margherita Rossi
Scopo dello studio

dimostrare che lo screening di una popolazione a rischio per cancro del pancreas permette:

  • diagnosi precoce
  • migliore sopravvivenza
Links
CONTATTI

E-Mail:
alber.ghini55@gmail.com

Contatto telefonico per visite intramoenia:
091229798

Indirizzo:
P.Za Leotta Nicola, 4, 90127 Palermo PA

SCRIVI UN MESSAGGIO

    Condividi su